Leerink Partners Remains Bullish as Fate Therapeutics (FATE) Plans to Initiate ProTmune Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Fate Therapeutics (FATE) Tops Q4 EPS by 1c
March 3, 2016 4:15 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $580 thousand.
Cash and cash equivalents as of December 31, 2015 were $64.8 million, compared to $49.1 million as of December... More
Trading Radar for 3/3: Barnes & Noble (BKS), Ciena (CIEN), HP Enterprise (HPE), H&R Block (HRB), Trina Solar (TSL) Report
March 2, 2016 3:00 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EST
Earnings:
Ability, Inc. (Nasdaq: ABIL) - consensus EPS $0.09
Agenus (Nasdaq: AGEN) - consensus loss $0.17
Alaska Communications Systems (Nasdaq: ALSK) - consensus loss $0.01
Ameresco (Nasdaq:... More
